Clinical trial
Randomised, Non-blind, Parallel Group Study to Compare Tandem High Dose Melphalan (200mg/m²) Versus Triple Intermediate Dose Melphalan (100mg/m²) and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy in Newly Diagnosed Patients With Multiple Myeloma
NCT00205764 is registered in ClinicalTrials.gov with Austrian Forum Against Cancer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomised, Non-blind, Parallel Group Study to Compare Tandem High Dose Melphalan (200mg/m²) Versus Triple Intermediate Dose Melphalan (100mg/m²) and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy in Newly Diagnosed Patients With Multiple Myeloma
- Lead sponsor
- Austrian Forum Against Cancer
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 31, 1999
- Completion date
- October 31, 2009
- Enrollment
- 212 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.